EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trial

Rakesh Ghosh iD, Olorunfemi Owa, Nicole Santos, Elizabeth Butrick, Gilda Piaggio, Mariana Widmer, Fernando Althabe, Zahaida Qureshi, Pisake Lumbiganon, Geetanjali Katageri, Dilys Walker

International Journal of Gynecology & Obstetrics · 2024-01 · 164 (1) · 124-130

DOI: 10.1002/ijgo.14938 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 26.06.2023. Verfasst von Rakesh Ghosh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health Sciences, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Postpartum Hemorrhage, Oxytocics, Biological Products. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, MSD K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine whether the observed non‐inferiority of heat‐stable carbetocin (HSC), compared with oxytocin, was influenced by biologic (macrosomia, parity 3 or more, or history of postpartum hemorrhage [PPH]) and/or pharmacologic (induction or augmentation) risk factors for PPH.

Methods

The present study is a secondary analysis of the CHAMPION non‐inferiority randomized trial—a two‐arm, double‐blind, active‐controlled study conducted at 23 hospitals in 10 countries, between July 2015 and January 2018. Women with singleton pregnancies, expected to deliver vaginally with cervical dilatation up to 6 cm were eligible. Randomization was stratified by country, with 1:1 assignment. Women in the intervention and control groups received a single intramuscular injection of 100 μg of HSC or 10 IU of oxytocin, respectively. The drugs were administered immediately after birth, and the third stage of labor was managed according to the WHO guidelines. Blood was collected using a plastic drape. For this analysis, we defined a woman as being at risk if she had any one or more of the biologic or pharmacologic risk factor(s).

Results

The HSC and oxytocin arms contained 14 770 and 14 768 women, respectively. The risk ratios (RR) for PPH were 1.29 (95% confidence interval [CI] 1.08–1.53) or 1.73 (95% CI 1.51–1.98) for those with only biologic (macrosomia, parity 3 or more, and PPH in the previous pregnancy) or only pharmacologic (induced or augmented) risk factors, respectively, compared with those with neither risk factors.

Conclusions

Findings reinforce previous evidence that macrosomia, high parity, history of PPH, and induction/augmentation are risk factors for PPH. We did not find a difference in effects between HSC and oxytocin for PPH among women who were neither induced nor augmented or among those who were induced or augmented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Postpartum HemorrhageOxytocicsBiological ProductsPregnancyFemaleHumansOxytocinHot TemperatureFetal MacrosomiaDouble-Blind Method

Stichwörter der Autor:innen

heat-stable carbetocinmanagementnon-inferiority trialoxytocintreatment

Substanzen

carbetocinOxytocinOxytocicsBiological Products

Autor:innen und Institutionen

  • Institute for Global Health Sciences, University of California, San Francisco, California, USA.
  • Department of Obstetrics and Gynecology, Mother and Child Hospital, Akure, Nigeria.
  • Statistika Consultoria, Campinas, Brazil.
  • Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
  • Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya.
  • Department of Obstetrics and Gynecology, Khon Kaen University, Bangkok, Thailand.

ORCID-Profile: Rakesh Ghosh

Förderung

  • World Health Organization
  • MSD K.K.

Zitieren

APA

Ghosh, R., Owa, O., Santos, N., Butrick, E., Piaggio, G., Widmer, M., Althabe, F., Qureshi, Z., Lumbiganon, P., Katageri, G., & Walker, D. (2024). Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trial. International Journal of Gynecology & Obstetrics, 164(1), 124-130. https://doi.org/10.1002/ijgo.14938

Vancouver

Ghosh R, Owa O, Santos N, Butrick E, Piaggio G, Widmer M, et al. Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trial. International Journal of Gynecology & Obstetrics. 2024;164(1):124-130. doi:10.1002/ijgo.14938

BibTeX
@article{Ghosh2024,
  author = {Ghosh, Rakesh and Owa, Olorunfemi and Santos, Nicole and Butrick, Elizabeth and Piaggio, Gilda and Widmer, Mariana and Althabe, Fernando and Qureshi, Zahaida and Lumbiganon, Pisake and Katageri, Geetanjali and Walker, Dilys},
  title = {Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trial},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2024},
  volume = {164},
  number = {1},
  pages = {124--130},
  doi = {10.1002/ijgo.14938}
}
Kostenlos starten →